Piero di Lorenzo

IRBM SpA is a research organization that specializes in drug discovery and development. IRBM is based in Pomezia, IT, and has subsidiaries in Italy. The Italian company produces recombinant proteins in a homogeneous state and use cyclization to pre-organize compounds for target binding. The private company uses nuclear magnetic resonance (NMR) spectroscopy to study structural biology, clinical research solutions, functional genomics, structure/activity relationships, drug discovery, macromolecule, and small-molecule analysis. The company has a screening library of over 320,000 compounds and use virtual screening and NMR to drive innovation. The company was founded in 2010 by Piero di Lorenzo, who has been the CEO since then.